Ranked #2,110 of 8,699 institutional investors
Gilead Sciences, Inc.
Foster City, CA
$1.19B
US stock portfolio at live prices · today −$10.7M (−0.89%)
Market closed. Prices as of Nov 20, 6:11 AM ET
- Value at quarter end (Q3 2026)
- $1.46B
- Change from Q2 2026
- −$184.9M (−11.21%)
- Positions
- 5 · 0 new, 0 sold out
- Filed
- Nov 6, 2026
Holdings
Q3 2026 13F, live pricesLKFT 46.9%RCUS 41.7%ASMB 9.42%KYTX 1.52%XLO 0.41%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| LKFT Lakefront Biotherapeutics NV | 16,707,477 | $558M | 46.9% | Unchanged |
| RCUS Arcus Biosciences, Inc. | 31,424,760 | $496M | 41.7% | Unchanged |
| ASMB Assembly Biosciences, Inc. | 4,977,089 | $112M | 9.42% | Unchanged |
| KYTX Kyverna Therapeutics, Inc. | 4,126,119 | $18.0M | 1.52% | Unchanged |
| XLO Xilio Therapeutics, Inc. | 650,389 | $4.9M | 0.41% | Unchanged |